Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 9, 2015, Pages 1545-1554

  Damien, Pauline ^a   Allan, David S ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Cellular therapy; Endothelial progenitor cells; Immunomodulation; Mesenchymal stromal cells; Regenerative medicine; Umbilical cord blood

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR BETA SUBUNIT; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL GROWTH; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION; COLONY FORMING CELL; CORD BLOOD STEM CELL TRANSPLANTATION; EMBRYONIC STEM CELL; ENDOTHELIAL COLONY FORMING CELL; ENDOTHELIAL PROGENITOR CELL; ENGRAFTMENT; FUCOSYLATION; GENE THERAPY; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MICROENVIRONMENT; NONHUMAN; PARACRINE SIGNALING; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TISSUE REGENERATION; VERY SMALL EMBRYONIC LIKE STEM CELL; ALLOGRAFT; FETUS BLOOD; IMMUNOLOGY; PROCEDURES;

ALLOGRAFTS; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HUMANS; IMMUNOMODULATION; REGENERATIVE MEDICINE;

EID: 84938937659     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.022     Document Type: Review

References (101)

1. Lim I.J., Phan T.T. Epithelial and mesenchymal stem cells from the umbilical cord lining membrane. Cell Transplant 2014, 23:497-503.
2. Flynn A., Barry F., O'Brien T. UC blood-derived mesenchymal stromal cells: an overview. Cytotherapy 2007, 9:717-726.
3. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007, 25:2896-2902.
4. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109:235-242.
5. Kikuchi-Taura A., Taguchi A., Kanda T., et al. Human umbilical cord provides a significant source of unexpanded mesenchymal stromal cells. Cytotherapy 2012, 14:441-450.
6. Dominici M., Le B.K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. Wagner W., Wein F., Seckinger A., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005, 33:1402-1416.
8. Kern S., Eichler H., Stoeve J., et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
9. Lee O.K., Kuo T.K., Chen W.M., et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103:1669-1675.
10. Wexler S.A., Donaldson C., Denning-Kendall P., et al. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003, 121:368-374.
11. Capelli C., Gotti E., Morigi M., et al. Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy 2011, 13:786-801.
12. Goodwin H.S., Bicknese A.R., Chien S.N., et al. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 2001, 7:581-588.
13. Romanov Y.A., Svintsitskaya V.A., Smirnov V.N. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003, 21:105-110.
14. Hou L., Cao H., Wang D., et al. Induction of umbilical cord blood mesenchymal stem cells into neuron-like cells in vitro. Int J Hematol 2003, 78:256-261.
15. Hong S.H., Gang E.J., Jeong J.A., et al. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun 2005, 330:1153-1161.
16. Pozzobon M., Franzin C., Piccoli M., De C.P. Fetal stem cells and skeletal muscle regeneration: a therapeutic approach. Front Aging Neurosci 2014, 6:222.
17. Gang E.J., Hong S.H., Jeong J.A., et al. In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells. Biochem Biophys Res Commun 2004, 321:102-108.
18. Del Fattore A., Luciano R., Saracino R., et al. Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells. Expert Opin Biol Ther 2015, 15:495-504.
19. Ahn J.O., Coh Y.R., Lee H.W., et al. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo. Anticancer Res 2015, 35:159-168.
20. De Lisio M., Jensen T., Sukiennik R.A., et al. Substrate and strain alter the muscle-derived mesenchymal stem cell secretome to promote myogenesis. Stem Cell Res Ther 2014, 5:74.
21. Rogers I., Casper R.F. Umbilical cord blood stem cells. Best Pract Res Clin Obstet Gynaecol 2004, 18:893-908.
22. Van Pham P., Kim P.N. Production of good manufacturing practice-grade human umbilical cord blood-derived mesenchymal stem cells for therapeutic use. Methods Mol Biol 2015, 1283:73-85.
23. Ishikawa F., Drake C.J., Yang S., et al. Transplanted human cord blood cells give rise to hepatocytes in engrafted mice. Ann N Y Acad Sci 2003, 996:174-185.
24. Wu H., Mahato R.I. Mesenchymal stem cell-based therapy for type 1 diabetes. Discov Med 2014, 17:139-143.
25. Anderson D.G., Markova D., An H.S., et al. Human umbilical cord blood-derived mesenchymal stem cells in the cultured rabbit intervertebral disc: a novel cell source for disc repair. Am J Phys Med Rehabil 2013, 92:420-429.
26. Carrade Holt D.D., Wood J.A., Granick J.L., et al. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev 2014, 23:1258-1265.
27. Akyurekli C., Le Y., Richardson R.B., et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell 2015, 11:150-160.
28. Iafolla M.A., Tay J., Allan D.S. Transplantation of umbilical cord blood-derived cells for novel indications in regenerative therapy or immune modulation: a scoping review of clinical studies. Biol Blood Marrow Transplant 2014, 20:20-25.
29. Dalous J., Larghero J., Baud O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. Pediatr Res 2012, 71:482-490.
30. Araya K., Sakai N., Mohri I., et al. Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation. Mol Genet Metab 2009, 98:255-263.
31. Higuchi T., Anton M., Dumler K., et al. Combined reporter gene PET and iron oxide MRI for monitoring survival and localization of transplanted cells in the rat heart. J Nucl Med 2009, 50:1088-1094.
32. Yu J., Li M., Qu Z., et al. SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal cells toward areas of heart myocardial infarction through activation of PI3K/Akt. J Cardiovasc Pharmacol 2010, 55:496-505.
33. Hofmann N.A., Ortner A., Jacamo R.O., et al. Oxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivo. PLoS One 2012, 7:e44468.
34. Honczarenko M., Le Y., Swierkowski M., et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, l24:1030-1041.
35. Ponte A.L., Marais E., Gallay N., et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745.
36. Sackstein R., Merzaban J.S., Cain D.W., et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008, 14:181-187.
37. Gao J., Dennis J.E., Muzic R.F., et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169:12-20.
38. Cho J.J., Malhi H., Wang R., et al. Enzymatically labeled chromosomal probes for in situ identification of human cells in xenogeneic transplant models. Nat Med 2002, 8:1033-1036.
39. Timmins N.E., Kiel M., Gunther M., et al. Closed system isolation and scalable expansion of human placental mesenchymal stem cells. Biotechnol Bioeng 2012, 109:1817-1826.
40. Secunda R., Vennila R., Mohanashankar A.M., et al. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study. Cytotechnology 2014, [Epub ahead of print].
41. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
42. Yoder M.C. Editorial: early and late endothelial progenitor cells are miR-tually exclusive. J Leukoc Biol 2013, 93:639-641.
43. Sun J., Li Y., Graziani G.M., et al. E-selectin mediated adhesion and migration of endothelial colony forming cells is enhanced by SDF-1alpha/CXCR4. PLoS One 2013, 8:e60890.
44. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7.
45. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
46. Au P., Daheron L.M., Duda D.G., et al. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood 2008, 111:1302-1305.
47. Hibbert B., Ma X., Pourdjabbar A., et al. Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. Cardiovasc Res 2009, 83:16-23.
48. Hibbert B., Lavoie J.R., Ma X., et al. Glycogen synthase kinase-3beta inhibition augments diabetic endothelial progenitor cell abundance and functionality via cathepsin B: a novel therapeutic opportunity for arterial repair. Diabetes 2014, 63:1410-1421.
49. Palii C.G., Vulesevic B., Fraineau S., et al. Trichostatin A enhances vascular repair by injected human endothelial progenitors through increasing the expression of TAL1-dependent genes. Cell Stem Cell 2014, 14:644-657.
50. Yu D., Chen W., Ren J., et al. VEGF-PKD1-HDAC7 signaling promotes endothelial progenitor cell migration and tube formation. Microvasc Res 2014, 91:66-72.
51. Yu M., Li Z., Shu Z., et al. Nicotine promotes late endothelial progenitor cells functional activity in a PI 3-kinase-dependent manner. Cell Biochem Biophys 2014, 70:1023-1028.
52. Sun S., Liu Z., Zhou H., et al. The role of fucosylation in the promotion of endothelial progenitor cells in neovascularization and bone repair. Biomaterials 2014, 35:3777-3785.
53. Chen J., Xiao X., Chen S., et al. Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic efficacy. Hypertension 2013, 61:681-689.
54. Moon S.H., Kim S.M., Park S.J., et al. Development of a xeno-free autologous culture system for endothelial progenitor cells derived from human umbilical cord blood. PLoS One 2013, 8:e75224.
55. Kogler G., Sensken S., Airey J.A., et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004, 200:123-135.
56. Kluth S.M., Buchheiser A., Houben A.P., et al. DLK-1 as a marker to distinguish unrestricted somatic stem cells and mesenchymal stromal cells in cord blood. Stem Cells Dev 2010, 19:1471-1483.
57. Capoccia B.J., Robson D.L., Levac K.D., et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 2009, 113:5340-5351.
58. Sondergaard C.S., Hess D.A., Maxwell D.J., et al. Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction. J Transl Med 2010, 8:24.
59. Hess D.A., Craft T.P., Wirthlin L., et al. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells 2008, 26:611-620.
60. Bhartiya D., Shaikh A., Nagvenkar P., et al. Very small embryonic-like stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous stem cell therapy. Stem Cells Dev 2012, 21:1-6.
61. Wang J., Gu Q., Hao J., et al. Generation of induced pluripotent stem cells with high efficiency from human umbilical cord blood mononuclear cells. Genomics Proteomics Bioinformatics 2013, 11:304-311.
62. Effenberg A., Stanslowsky N., Klein A., et al. Striatal transplantation of human dopaminergic neurons differentiated from induced pluripotent stem cells derived from umbilical cord blood using lentiviral reprogramming. Cell Transplant 2014, [Epub ahead of print].
63. Warren L., Manos P.D., Ahfeldt T., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
64. Hong H., Takahashi K., Ichisaka T., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
65. Lee S.H., Lee M.W., Yoo K.H., et al. Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplant 2013, 48:1040-1045.
66. Nuzzolo E.R., Capodimonti S., Martini M., et al. Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. Blood Transfus 2014, 12(Suppl 1):s367-s374.
67. Jung J., Moon N., Ahn J.Y., et al. Mesenchymal stromal cells expanded in human allogenic cord blood serum display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev 2009, 18:559-571.
68. Gottipamula S., Muttigi M.S., Kolkundkar U., Seetharam R.N. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif 2013, 46:608-627.
69. Hemeda H., Giebel B., Wagner W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy 2014, 16:170-180.
70. Huang L., Critser P.J., Grimes B.R., Yoder M.C. Human umbilical cord blood plasma can replace fetal bovine serum for in vitro expansion of functional human endothelial colony-forming cells. Cytotherapy 2011, 13:712-721.
71. Porada C.D., Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 2010, 62:1156-1166.
72. Nomura T., Honmou O., Harada K., et al. I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 2005, 136:161-169.
73. Liu H., Honmou O., Harada K., et al. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006, 129:2734-2745.
74. Ding D.C., Shyu W.C., Chiang M.F., et al. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis 2007, 27:339-353.
75. Ozawa K., Sato K., Oh I., et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008, 30:121-127.
76. Kim S.M., Lim J.Y., Park S.I., et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008, 68:9614-9623.
77. Zhang X., Zhang L., Xu W., et al. Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets 2013, 13:92-102.
78. Gul-Uludag H., Xu P., Marquez-Curtis L.A., et al. Cationic liposome-mediated CXCR4 gene delivery into hematopoietic stem/progenitor cells: implications for clinical transplantation and gene therapy. Stem Cells Dev 2012, 21:1587-1596.
79. Li X., Gervaix A., Kang D., et al. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Gene Ther 1998, 5:233-239.
80. Petz L.D., Redei I., Bryson Y., et al. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant 2013, 19:393-397.
81. Cornu T.I., Mussolino C., Bloom K., Cathomen T. Editing CCR5: a novel approach to HIV gene therapy. Adv Exp Med Biol 2015, 848:117-130.
82. Peris P., Roforth M.M., Nicks K.M., et al. Ability of circulating human hematopoietic lineage negative cells to support hematopoiesis. J Cell Biochem 2015, 116:58-66.
83. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10:244-258.
84. Wu K.H., Sheu J.N., Wu H.P., et al. Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation 2013, 95:773-777.
85. Xiong Y.Y., Fan Q., Huang F., et al. Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: a pilot prospective, open-label, randomized trial. Biol Blood Marrow Transplant 2014, 20:236-242.
86. de Lima M., McNiece I., Robinson S.N., et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012, 367:2305-2315.
87. Francese R., Fiorina P. Immunological and regenerative properties of cord blood stem cells. Clin Immunol 2010, 136:309-322.
88. Wang M., Yang Y., Yang D., et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology 2009, 126:220-232.
89. Le B.K., Rasmusson I., Gotherstrom C., et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004, 60:307-315.
90. Cutler A.J., Limbani V., Girdlestone J., Navarrete C.V. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol 2010, 185:6617-6623.
91. Chatterjee D., Marquardt N., Tufa D., et al. Role of gamma-secretase in human umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell cytotoxicity. Cell Commun Signal 2014, 12:63.
92. Kim E.S., Chang Y.S., Choi S.J., et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respir Res 2011, 12:108.
93. Zhao Y., Jiang Z., Zhao T., et al. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med 2013, 11:160.
94. Jeong S.Y., Kim D.H., Ha J., et al. Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation. Stem Cells 2013, 31:2136-2148.
95. Teixeira F.G., Carvalho M.M., Sousa N., Salgado A.J. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?. Cell Mol Life Sci 2013, 70:3871-3882.
96. Baglio S.R., Pegtel D.M., Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 2012, 3:359.
97. Kinnaird T., Stabile E., Burnett M.S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
98. Herrmann J.L., Wang Y., Abarbanell A.M., et al. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock 2010, 33:24-30.
99. Huang X., Sun K., Zhao Y.D., et al. Human CD34+ progenitor cells freshly isolated from umbilical cord blood attenuate inflammatory lung injury following LPS challenge. PLoS One 2014, 9:e88814.
100. Lee J.H., Hah Y.S., Cho H.Y., et al. Human umbilical cord blood-derived CD34-positive endothelial progenitor cells stimulate osteoblastic differentiation of cultured human periosteal-derived osteoblasts. Tissue Eng Part A 2014, 20:940-953.
101. Ratajczak J., Kucia M., Mierzejewska K., et al. Paracrine proangiopoietic effects of human umbilical cord blood-derived purified CD133+ cells-implications for stem cell therapies in regenerative medicine. Stem Cells Dev 2013, 22:422-430.